NEW YORK (GenomeWeb News) – Illumina said in a filing with the US Securities and Exchange Commission this week that Paul Grint plans to retire from the firm's board of directors, effective as of the next Illumina stockholder meeting.

Grint has been a director since 2005. He currently is senior VP at Forest Research Institute, and he previously was CMO at Kalypsys. He also has served as an executive at Zephyr Sciences, Pfizer, IDEC Pharmaceuticals, and Schering-Plough.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.